The National Company for Glass Industries (TADAWUL:2150)
Saudi Arabia · Delayed Price · Currency is SAR 41.24
+0.44 (1.08%)
Aug 13, 2025, 3:13 PM AST
Ligand Pharmaceuticals Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 138.38 | 138.93 | 153.92 | 112.32 | 86.93 | 73.3 | Upgrade | |
Revenue Growth (YoY) | -3.45% | -9.74% | 37.04% | 29.20% | 18.59% | -2.08% | Upgrade |
Cost of Revenue | 107.35 | 105.74 | 119.6 | 109.52 | 83.49 | 76.3 | Upgrade |
Gross Profit | 31.03 | 33.19 | 34.32 | 2.8 | 3.44 | -2.99 | Upgrade |
Selling, General & Admin | 20.21 | 19.49 | 15.82 | 13.53 | 11.28 | 12.14 | Upgrade |
Other Operating Expenses | -3.23 | -3.23 | -2.63 | -0.85 | -0.18 | -0.44 | Upgrade |
Operating Expenses | 17.22 | 16.26 | 13.19 | 13.36 | 16.21 | 12.65 | Upgrade |
Operating Income | 13.81 | 16.93 | 21.13 | -10.56 | -12.76 | -15.64 | Upgrade |
Interest Expense | -1.14 | -0.82 | -3.3 | -3.28 | -2.4 | -3.03 | Upgrade |
Earnings From Equity Investments | 77.32 | 85.51 | 36.38 | 126.78 | 73.24 | 10.24 | Upgrade |
Currency Exchange Gain (Loss) | -0.36 | -0.36 | -0.3 | -0.07 | -0.03 | -0.12 | Upgrade |
EBT Excluding Unusual Items | 89.63 | 101.26 | 53.92 | 112.87 | 58.04 | -8.54 | Upgrade |
Gain (Loss) on Sale of Investments | -1.48 | -1.48 | -0.59 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.17 | 0.17 | 0.01 | - | 0.04 | 0 | Upgrade |
Asset Writedown | - | - | -0.17 | - | -1.42 | - | Upgrade |
Other Unusual Items | - | - | - | - | 1.07 | 0.36 | Upgrade |
Pretax Income | 88.33 | 99.96 | 53.17 | 112.87 | 57.73 | -8.18 | Upgrade |
Income Tax Expense | 3.06 | 3.13 | 5.29 | 2.88 | 4.17 | 2.85 | Upgrade |
Earnings From Continuing Operations | 85.26 | 96.83 | 47.88 | 109.99 | 53.56 | -11.04 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -5.66 | -2.45 | - | Upgrade |
Net Income | 85.26 | 96.83 | 47.88 | 104.33 | 51.11 | -11.04 | Upgrade |
Net Income to Common | 85.26 | 96.83 | 47.88 | 104.33 | 51.11 | -11.04 | Upgrade |
Net Income Growth | -3.75% | 102.24% | -54.11% | 104.11% | - | - | Upgrade |
Shares Outstanding (Basic) | 33 | 33 | 33 | 33 | 33 | 33 | Upgrade |
Shares Outstanding (Diluted) | 33 | 33 | 33 | 33 | 33 | 33 | Upgrade |
EPS (Basic) | 2.59 | 2.94 | 1.46 | 3.17 | 1.55 | -0.34 | Upgrade |
EPS (Diluted) | 2.59 | 2.94 | 1.46 | 3.17 | 1.55 | -0.34 | Upgrade |
EPS Growth | -3.75% | 102.24% | -54.11% | 104.11% | - | - | Upgrade |
Free Cash Flow | -39.72 | -22.61 | 29.15 | -0.74 | -8.05 | -10.75 | Upgrade |
Free Cash Flow Per Share | -1.21 | -0.69 | 0.89 | -0.02 | -0.24 | -0.33 | Upgrade |
Dividend Per Share | 0.900 | 1.500 | 1.000 | 1.000 | 0.500 | - | Upgrade |
Dividend Growth | -18.18% | 50.00% | - | 100.00% | - | - | Upgrade |
Gross Margin | 22.42% | 23.89% | 22.30% | 2.49% | 3.96% | -4.08% | Upgrade |
Operating Margin | 9.98% | 12.19% | 13.73% | -9.40% | -14.68% | -21.34% | Upgrade |
Profit Margin | 61.61% | 69.70% | 31.11% | 92.89% | 58.80% | -15.05% | Upgrade |
Free Cash Flow Margin | -28.70% | -16.28% | 18.94% | -0.66% | -9.26% | -14.66% | Upgrade |
EBITDA | 46.02 | 46.49 | 52.39 | 22.43 | 15.89 | 11.51 | Upgrade |
EBITDA Margin | 33.26% | 33.46% | 34.03% | 19.97% | 18.28% | 15.70% | Upgrade |
D&A For EBITDA | 32.21 | 29.56 | 31.26 | 32.99 | 28.65 | 27.15 | Upgrade |
EBIT | 13.81 | 16.93 | 21.13 | -10.56 | -12.76 | -15.64 | Upgrade |
EBIT Margin | 9.98% | 12.19% | 13.73% | -9.40% | -14.68% | -21.34% | Upgrade |
Effective Tax Rate | 3.47% | 3.13% | 9.95% | 2.55% | 7.22% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.